| Active substance | Vedolizumab |
| Holder | Takeda |
| Status | Closed |
| Indication | Patients with Crohn disease that have failed at least 2 previous anti-TNF or for whom anti-TNF is contra-indicated |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 03/05/2016 |
Entyvio®
Last updated on 03/04/2024